Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06824181 · ClinicalTrials.gov registry record · Phase 3
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
A Phase 3 study of Pneumococcal Immunization, sponsored by Sanofi.
- Active
- Registry status
- Phase 3
- Development phase
- 580
- Enrollment target
- 20
- Study locations
NCT06824181: Active Phase 3 study of Pneumococcal Immunization, sponsored by Sanofi.
NCT06824181 is a Phase 3 study of Pneumococcal Immunization that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 580 participants, below the 1,403-participant average among 3 other Pneumococcal Immunization trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06824181, a Phase 3 study of Pneumococcal Immunization, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 580 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) when it is given after 1 dose, 2 doses, or 3 doses of a licensed 20-valent pneumococcal vaccine compared to when 20-valent pneumococcal vaccine is given as a complete series in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age (MoA). Routine pediatric vaccines will be given as per local recommendations. There will be 6 study visits: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age until 15 months of age, V06 separated from V05 by 30 days.
Primary Outcome
Number of participants experiencing solicited and unsolicited immediate AEs
Conditions Studied
Interventions
- BIOLOGICAL PCV21 vaccine
- BIOLOGICAL Prevnar 20 vaccine
- BIOLOGICAL M-M-R II vaccine
- BIOLOGICAL Rotarix
- BIOLOGICAL RotaTeq
Study Locations (20)
Texas
- Helios Clinical Research - BUR PEDI- Site Number : 8400016 - Burleson
- Clinsearch Inc at VAST Clinical Research- Site Number : 8400028 - Euless
- DM Clinical Research - Houston - Jones Road- Site Number : 8400012 - Houston
- University of Texas Medical Branch at Galveston- Site Number : 8400005 - League City
- Javara - Privia Medical Group North Texas - Stephenville- Site Number : 8400024 - Stephenville
Florida
- The Medici Medical Research- Site Number : 8400008 - Hollywood
- Clinsearch Inc at Dr. Gala, LLC- Site Number : 8400027 - Miami
- Atlantis Clinical Research- Site Number : 8400009 - Miami
New York
- Finger Lakes Medical Research - Cortland- Site Number : 8400022 - Cortland
- University of Rochester Medical Center- Site Number : 8400019 - Rochester
- SUNY Upstate Medical University - Syracuse- Site Number : 8400015 - Syracuse
Reg Metropolitana de Santiago
- Investigational Site Number : 1520003 - Santiago
- Investigational Site Number : 1520002 - Santiago
- Investigational Site Number : 1520001 - Santiago
California
- Kaiser Permanente - Los Angeles Medical Center- Site Number : 8400025 - Los Angeles
Iowa
- Velocity Clinical Research - Sioux City- Site Number : 8400007 - Sioux City
Kentucky
- Private Practice - Dr. Michael W. Simon- Site Number : 8400001 - Lexington
Louisiana
- Velocity Clinical Research - New Orleans- Site Number : 8400006 - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 580 participants |
| Start Date | 2025-02-27 |
| Est. Completion | 2027-09-10 |
| Phase | Phase 3 |
What the registry record for NCT06824181 still lists
NCT06824181 is an interventional study that assigns participants to a tested intervention. The registered 580 participants enrollment target is mid-sized for trials with a published cap, below the 1,403-participant average among 3 other Pneumococcal Immunization trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Pneumococcal Immunization appearing as the primary indexed condition, and to 5 interventions - of which PCV21 vaccine is the first listed.
NCT06824181 names 20 study sites across 10 states, led by Texas, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06824181 about?
NCT06824181 is a clinical study titled "Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age". This study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) when it is given after 1 dose, 2 doses, or 3 dose...
What is the current status of trial NCT06824181?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 580 participants. The study started on 2025-02-27. Estimated completion is 2027-09-10.
What conditions does trial NCT06824181 study?
This clinical trial studies the following conditions: Pneumococcal Immunization.
What interventions are being tested in trial NCT06824181?
The interventions under investigation include: PCV21 vaccine (BIOLOGICAL), Prevnar 20 vaccine (BIOLOGICAL), M-M-R II vaccine (BIOLOGICAL), Rotarix (BIOLOGICAL), RotaTeq (BIOLOGICAL).
Who is sponsoring clinical trial NCT06824181?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06824181 being conducted?
This trial has 20 study locations across California, Florida, Iowa, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumococcal Immunization
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
RECRUITING · Phase 3
-
Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- NCT05143177 · 580 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
- NCT05696353 · 580 participants · Phase 3
Teen Driving Translation Study (NIH)
- NCT06578104 · 580 participants
PULSED AF Post-Approval Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI